Impact of pharmacological and non-pharmacological interventions on mortality in chronic obstructive pulmonary disease (COPD) patients.

[1]  G. Verleden,et al.  Lung transplantation for COPD/pulmonary emphysema , 2023, European Respiratory Review.

[2]  W. Banya,et al.  Lung volume reduction surgery versus endobronchial valves: a randomised controlled trial , 2023, European Respiratory Journal.

[3]  P. Venkatesan.  GOLD COPD report: 2023 update. , 2022, The Lancet. Respiratory medicine.

[4]  M. Cazzola,et al.  Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score , 2022, Journal of clinical medicine.

[5]  C. la Vecchia,et al.  Chronic obstructive pulmonary disease (COPD) mortality trends worldwide: An update to 2019 , 2022, Respirology.

[6]  R. Casaburi,et al.  Home oxygen for moderate hypoxaemia in chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2022, The Lancet. Respiratory medicine.

[7]  P. J. Z. Teixeira,et al.  Association of Reduced BMI, length of hospital stay, mortality, and malnutrition diagnosis in COPD patients with acute exacerbation: A secondary analysis of a cohort study. , 2022, JPEN. Journal of parenteral and enteral nutrition.

[8]  D. Slebos,et al.  Survival in COPD patients treated with bronchoscopic lung volume reduction. , 2022, Respiratory medicine.

[9]  Chih-Cheng Lai,et al.  The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2022, Life.

[10]  A. Matsunaga,et al.  Pulmonary Rehabilitation for Patients After COPD Exacerbation , 2021, Respiratory Care.

[11]  C. Butler,et al.  Statin prescription in patients with chronic obstructive pulmonary disease and risk of exacerbations: a retrospective cohort study in the Clinical Practice Research Datalink , 2021, BMJ Open.

[12]  E. Regan,et al.  Longitudinal association between muscle loss and mortality in ever-smokers , 2021, Chest.

[13]  P. Calverley,et al.  Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT , 2021, Annals of the American Thoracic Society.

[14]  J. Vonk,et al.  Chronic non-invasive ventilation for chronic obstructive pulmonary disease. , 2021, The Cochrane database of systematic reviews.

[15]  G. Ignatova,et al.  Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study , 2021, Scientific Reports.

[16]  F. Cendes,et al.  Brain Structural Signature of RFC1‐Related Disorder , 2021, Movement disorders : official journal of the Movement Disorder Society.

[17]  N. Kolaitis,et al.  Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  S. Suissa.  Perplexing mortality data from triple therapy trials in COPD. , 2021, The Lancet. Respiratory medicine.

[19]  C. Ulrik,et al.  Statins in High-Risk Chronic Obstructive Pulmonary Disease Outpatients: No Impact on Time to First Exacerbation and All-Cause Mortality – The STATUETTE Cohort Study , 2021, International journal of chronic obstructive pulmonary disease.

[20]  Chang-Hoon Lee,et al.  Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis , 2020, Respiratory Research.

[21]  Jinghua Yang,et al.  Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis , 2020, European heart journal.

[22]  B. Redwan,et al.  Lung volume reduction surgery: from National Emphysema Treatment Trial to non-intubated awake video-assisted thoracoscopic surgery , 2020, Annals of translational medicine.

[23]  Y. Lacasse,et al.  Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease. , 2020, The New England journal of medicine.

[24]  N. Deutz,et al.  Reduced mortality risk in malnourished hospitalized older adult patients with COPD treated with a specialized oral nutritional supplement: Sub-group analysis of the NOURISH study. , 2020, Clinical nutrition.

[25]  C. Torp‐Pedersen,et al.  Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study , 2020, Thorax.

[26]  S. Tarantini,et al.  Prevalence of influenza and pneumococcal vaccination in chronic obstructive pulmonary disease patients in association with the occurrence of acute exacerbations , 2020, Journal of thoracic disease.

[27]  P. Dorinsky,et al.  Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.

[28]  R. Zuwallack,et al.  Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. , 2020, JAMA.

[29]  Meilan K. Han,et al.  Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients. , 2020, American journal of respiratory and critical care medicine.

[30]  Adam S. LaPrad,et al.  5-Year Survival after Endobronchial Coil Implantation: Secondary Analysis of the First Randomised Controlled Trial, RESET , 2020, Respiration.

[31]  J. Curtis,et al.  Metoprolol for the Prevention of Acute Exacerbations of COPD. , 2019, The New England journal of medicine.

[32]  G. Verleden,et al.  Azithromycin during Acute COPD Exacerbations Requiring Hospitalization (BACE): a Multicentre, Randomized, Double-blind, Placebo-controlled Trial. , 2019, American journal of respiratory and critical care medicine.

[33]  J. Vonk,et al.  Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial , 2019, Thorax.

[34]  J. Gensel,et al.  Macrolide derivatives reduce proinflammatory macrophage activation and macrophage‐mediated neurotoxicity , 2019, CNS neuroscience & therapeutics.

[35]  I. Farver-Vestergaard,et al.  Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis , 2018, BMC Pulmonary Medicine.

[36]  P. Poole,et al.  Influenza vaccine for chronic obstructive pulmonary disease (COPD). , 2018, The Cochrane database of systematic reviews.

[37]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[38]  M. Cazzola,et al.  The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis , 2017, International journal of chronic obstructive pulmonary disease.

[39]  J. Wedzicha,et al.  Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial , 2017, JAMA.

[40]  D. Stefanidis,et al.  Seasonal influenza vaccination in patients with COPD: a systematic literature review , 2017, BMC Pulmonary Medicine.

[41]  P. Lange,et al.  Socioeconomic inequalities in adherence to inhaled maintenance medications and clinical prognosis of COPD. , 2016, Respiratory medicine.

[42]  J. Sundh,et al.  Long-Term Oxygen Therapy 24 vs 15 h/day and Mortality in Chronic Obstructive Pulmonary Disease , 2016, PloS one.

[43]  F. Herth,et al.  Survival after Endoscopic Valve Therapy in Patients with Severe Emphysema , 2016, Respiration.

[44]  N. Roche,et al.  Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study. , 2016, Respiratory medicine.

[45]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[46]  K. Koehorst-ter Huurne,et al.  Statins and morbidity and mortality in COPD in the COMIC study: a prospective COPD cohort study , 2016, BMJ Open Respiratory Research.

[47]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[48]  Huahao Shen,et al.  The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: a systematic review and meta-analysis of observational research , 2015, Scientific Reports.

[49]  C. Cates,et al.  Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. , 2015, The Cochrane database of systematic reviews.

[50]  H. Neffen,et al.  A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD. , 2015, Chest.

[51]  K. Jørgensen,et al.  Danish evidence-based clinical guideline for use of nutritional support in pulmonary rehabilitation of undernourished patients with stable COPD. , 2015, Clinical nutrition ESPEN.

[52]  E. Dabscheck,et al.  Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease. , 2015, The Cochrane database of systematic reviews.

[53]  J. Hallas,et al.  Statin use and exacerbations in individuals with chronic obstructive pulmonary disease , 2014, Thorax.

[54]  Stefano Nava,et al.  Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. , 2014, The Lancet. Respiratory medicine.

[55]  Sally J. Singh,et al.  An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial , 2014, BMJ : British Medical Journal.

[56]  Meilan K. Han,et al.  Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. , 2014, The New England journal of medicine.

[57]  R. DiSantostefano,et al.  Risk of Pneumonia with Inhaled Corticosteroid versus Long-Acting Bronchodilator Regimens in Chronic Obstructive Pulmonary Disease: A New-User Cohort Study , 2014, PloS one.

[58]  Y. Oba,et al.  Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis , 2014, International journal of chronic obstructive pulmonary disease.

[59]  J. Vonk,et al.  Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study , 2014, Thorax.

[60]  P. Poole,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[61]  P. Poole,et al.  Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[62]  Dacheng Liu,et al.  Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. , 2012, Respiratory medicine.

[63]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[64]  J. Vonk,et al.  Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: A randomized controlled trial , 2011, Respiratory research.

[65]  J. Mann,et al.  Obesity and Mortality in Persons with Obstructive Lung Disease Using Data from the NHANES III , 2010, Southern medical journal.

[66]  P. Soccal,et al.  Survival impact of lung transplantation for COPD , 2009, European Respiratory Journal.

[67]  M. Decramer,et al.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[68]  J A Anderson,et al.  Adherence to inhaled therapy, mortality and hospital admission in COPD , 2009, Thorax.

[69]  T. MacDonald,et al.  Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD , 2009, Thorax.

[70]  R. Mcevoy,et al.  Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial , 2009, Thorax.

[71]  Yoon K Loke,et al.  Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. , 2009, Archives of internal medicine.

[72]  J. Vestbo,et al.  COPD-related morbidity and mortality after smoking cessation: status of the evidence , 2008, European Respiratory Journal.

[73]  M. Anstead,et al.  Azithromycin alters macrophage phenotype. , 2008, The Journal of antimicrobial chemotherapy.

[74]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[75]  John Connett,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[76]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[77]  D. Strachan,et al.  Validity and interpretation of mortality, health service and survey data on COPD and asthma in England , 2003, European Respiratory Journal.

[78]  L. Sharples,et al.  Assessment of survival benefit after lung transplantation by patient diagnosis. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[79]  B. Celli,et al.  Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. , 2000, Chest.

[80]  A. Chaouat,et al.  A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. , 1999, The European respiratory journal.

[81]  R. Novick,et al.  Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease , 1998, The Lancet.

[82]  E. Fletcher,et al.  A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. , 1992, The American review of respiratory disease.

[83]  Cotes Je,et al.  LONG TERM DOMICILIARY OXYGEN THERAPY IN CHRONIC HYPOXIC COR PULMONALE COMPLICATING CHRONIC BRONCHITIS AND EMPHYSEMA Report of the Medical Research Council Working Party , 1981, The Lancet.

[84]  J. Benichou,et al.  [A multi-centre randomized controlled trial of domiciliary non-invasive ventilation vs long-term oxygen therapy in survivors of acute hypercapnic respiratory failure due to COPD. Non-invasive ventilation in obstructive lung disease (NIVOLD) study]. , 2012, Revue des maladies respiratoires.

[85]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.

[86]  Ø. Borgan,et al.  Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[87]  N. Anthonisen.  Lessons from the Lung Health Study. , 2004, Proceedings of the American Thoracic Society.

[88]  E. Wouters,et al.  Weight Loss Is a Reversible Factor in the Prognosis of Chronic Obstructive Pulmonary Disease , 1998 .

[89]  Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. , 1980, Annals of internal medicine.